Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 4:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–9 of 9 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Volanesorsen Clear all
Completed Phase 3 Interventional Results available

The APPROACH Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome

NCT02211209
View directory record Official record
Conditions
Familial Chylomicronemia Syndrome
Interventions
Volanesorsen, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
11
States / cities
Encinitas, California • San Francisco, California • Kansas City, Kansas + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Oct 19, 2026, 4:24 AM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety and Tolerability of ISIS 304801 in People With Partial Lipodystrophy With an Open-Label Extension

NCT02639286
View directory record Official record
Conditions
Lipodystrophy
Interventions
ISIS 304801, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2020 · Synced Oct 19, 2026, 4:24 AM EDT
Terminated Phase 2 Interventional

Mechanistic Study of ISIS ISIS-APOCIIIRX in Type 2 Diabetes

NCT01647308
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
ISIS-APOCIIIRX, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Oct 19, 2026, 4:24 AM EDT
Completed Phase 3 Interventional Results available

The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia

NCT02300233
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Volanesorsen, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
29
States / cities
Encinitas, California • San Francisco, California • Boca Raton, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Oct 19, 2026, 4:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Volanesorsen on Cardiac Repolarization Conducted in Healthy Volunteers

NCT02910635
View directory record Official record
Conditions
Abnormalities, Cardiovascular
Interventions
Volanesorsen, Moxifloxacin, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 28, 2022 · Synced Oct 19, 2026, 4:24 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

The BROADEN Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Partial Lipodystrophy

NCT02527343
View directory record Official record
Conditions
Familial Partial Lipodystrophy
Interventions
volanesorsen, Placebo
Drug
Lead sponsor
Akcea Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
6
States / cities
Ann Arbor, Michigan • Rochester, Minnesota • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Oct 19, 2026, 4:24 AM EDT
Completed Phase 2 Interventional

Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia

NCT01529424
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
ISIS apoC-III Rx, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
6
States / cities
Farmville, North Carolina • Greenville, North Carolina • Kinston, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2022 · Synced Oct 19, 2026, 4:24 AM EDT
Completed Phase 3 Interventional Results available

The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Chylomicronemia Syndrome

NCT02658175
View directory record Official record
Conditions
Familial Chylomicronemia Syndrome, Lipoprotein Lipase Deficiency, Hyperlipoproteinemia Type 1
Interventions
Volanesorsen
Drug
Lead sponsor
Akcea Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
8
States / cities
Huntington Beach, California • San Francisco, California • Boca Raton, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2021 · Synced Oct 19, 2026, 4:24 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Treated With Volanesorsen

NCT05185843
View directory record Official record
Conditions
Familial Chylomicronemia Syndrome
Interventions
Olezarsen
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Huntington Beach, California • Boca Raton, Florida • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 19, 2026, 4:24 AM EDT